Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.

ABSTRACT:

Objective

To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD).

Methods

Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing.

Results

Substantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0-5.0] years, AD = 2.5 [0-8.0] years; p = 0.96), and median (range) baseline dementia severity (Clinical De

SUBMITTER: Day GS 

PROVIDER: S-EPMC5373780 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature